Related Experiment Videos
Effects of dexamethasone on the hypothalamic-pituitary-adrenal axis in preterm infants
Z B Rizvi1, H S Aniol, T F Myers
1Section of Neonatology, Loyola University Medical Center, Maywood, Illinois 60153.
Insights
Dexamethasone therapy significantly suppresses the hypothalamic-pituitary-adrenal axis in premature infants with bronchopulmonary dysplasia. This suppression primarily occurs at the pituitary gland level after seven days of treatment.
Area of Science:
- Pediatric Endocrinology
- Neonatal Physiology
- Pharmacodynamics
Background:
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting premature infants.
- Corticosteroids like dexamethasone are used to manage BPD inflammation.
- The hypothalamic-pituitary-adrenal (HPA) axis regulates stress response and metabolism.
Purpose of the Study:
- To evaluate the impact of dexamethasone therapy on HPA axis function in premature infants with BPD.
- To determine the specific site of HPA axis suppression during dexamethasone treatment.
Main Methods:
- The study involved 10 premature infants diagnosed with bronchopulmonary dysplasia.
- The corticotropin-releasing hormone (CRH) stimulation test was administered before and on day 7 of dexamethasone therapy.
- Radioimmunoassay was used to measure adrenocorticotropic hormone (ACTH) and cortisol levels.
Main Results:
- Dexamethasone therapy resulted in significant suppression of the HPA axis.
- The suppression was evident by the seventh day of treatment.
- Analysis indicated that the pituitary gland was a primary site of this dexamethasone-induced suppression.
Conclusions:
- Current dexamethasone treatment regimens for bronchopulmonary dysplasia cause significant HPA axis suppression in premature infants.
- The pituitary gland is identified as a key location for this suppressive effect.
- Further research may be needed to optimize dexamethasone dosing to mitigate HPA axis dysfunction.
Abstract:
The effects of dexamethasone therapy on the hypothalamic-pituitary-adrenal axis were tested in 10 premature infants with bronchopulmonary dysplasia by means of the corticotropin-releasing hormone stimulation test before therapy and on the seventh day of therapy. Adrenocorticotropic hormone and cortisol levels were determined by radioimmunoassay. There was significant suppression of the hypothalamic-pituitary-adrenal axis after 7 days of a currently used dexamethasone treatment regimen. A site of suppression was located at the level of the pituitary gland.